佐思市场研究报告网
首页 登陆 网站地图 联系我们
研究报告
报告定制
资料下载
竞争情报
行业情报
企业研究
佐思软件
咨询行业
我和佐思
English
您现在的位置: 佐思市场研究报告网 > ENGLISH > Life Sciences > Pharmaceutical > Roport正文
Tel
86-10-82600828
86-10-82600893
Fax
86-10-82600829
Mail:
Beneficial Name:Beijing Waterwood Technologies CO.,LTD
Bank Name: Bank of Communications, Beijing Branch
Bank Address: NO.1 jinxiyuan shijicheng,Landianchang,Haidian District,Beijing
Bank Account No #: 110060668012015061217
Routing No # : 332906
Bank SWIFT Code :COMMCNSHBJG

Navigation
Consumer Goods
Food/Beverage
Heavy Industry
Life Sciences
Technology&Media
Service Industries
[图文]Company Study of Huadong Medicine
Company Study of Huadong Medicine
作者:佚名    Roport来源:本站原创    点击数:    更新时间:2008-5-14
发表评论】【加入收藏】【告诉好友】【打印此文】【关闭窗口】【Text:Little louge

Abstract


Huadong Medicine Co., Ltd. was founded in March, 1993, based on the medicine distribution network in Hanzhou, capital of Zhejiang province, after a government-oriented restructuring. On December 22, 1999, the company went public on the Shenzhen Stock Exchange and raised around CNY288 million through issuing 5,000 shares. Its main business covers the production and sale of chemical medicine and traditional Chinese medicine.

Structure of Main Business Revenue of Huadong Medicine


(Unit: CNY billion)
 
Source: ResearchInChina

Huadong Medicine's main business revenue covers two parts-pharmacy industry and pharmacy business. Since the gross profit margin of pharmacy industry is much higher than the pharmacy business, Huadong Medicine has been making vigorous efforts to open up the market of the pharmacy industry, which has made the proportion of its pharmacy industry to the total main business revenue increase year by year. This is one of the key reasons that the company's performance rose gradually in the recently years.

According to the company's announcement on April 3, 2008, Huadong Medicine plans to acquire 78.87% stake in Xi'an Bohua Pharmaceutical Co., Ltd. and 65% stake in the latter's subsidiary named Shaanxi Jiuzhou Medicine Co., Ltd. for CNY98 million. The acquisition, if done, will not only help the company reinforce its strength in special pharmaceutical raw materials, but also enter the narcotic market with high barriers to enter.

Table of Contents


1. Huadong Medicine Company Profile
1.1 Brief Introduction
1.2 Shareholders of Huadong Medicine
1.3 Pharmacy Policies
1.3.1 Hospital to Follow the Measures for Prescription Management
1.3.2 Industry Concentration to Be Lifted Greatly by Improved Environment Protection Standards

2. Main Business of Huadong Medicine 
2.1 Products
2.2 Pharmacy Industry
2.2.1 Immunosuppressant Products
2.2.2 Diabetes Medicines
2.2.3 Anti-peptic ulcer medicine
2.2.4 Pharmaceutical Raw Material
2.2.5 Summery on Pharmacy Industry 
2.3 Pharmacy Business 
2.4 Marketing and Development Strategies
2.4.1 Marketing Strategy
2.4.2 Development Strategy

3. Financial Status of Huadong Medicine Co., LTD
3.1 Solvency 
3.2 Operation Efficiency
3.3 Profitability
3.4 Growing Ability
3.5 Financial Structure
3.6 Cash Flow Ratio

4. SWOT Analysis
4.1 Strength 
4.2 Weakness
4.3 Opportunities 
4.4 Threats

5. Summarization 

Selected Charts


Huadong Medicine's Shareholding Structure 
Huadong Medicine's Organization Structure 
Huadong Medicine's Top Ten Shareholders As of 2007
Huadong Medicine's Main Products
Huadong Medicine's Main Businesses, 2003-2007
Huadong Medicine's Business Structure in 2007
Huadong Medicine's Gross Profit Margin, 2003-2007
Companies Producing Main Products of Huadong Medicine
Huadong Medicine's Sales Revenue by Product, 2007
Huadong Medicine's Sales Revenue of Main Products 
Huadong Medicine's Pharmacy Industry Performance, 1998-2007
Huadong Medicine's Distribution Targets in 2006 
Development Thought of the Western Medicine Sector
Huadong Medicine's Sales Revenue and Growth by Product, 2004-2008
Distribution of China Immunosuppressant Market Share
Purchasing Value of Sampled Immunosuppressant in Typical Cities of China
Growth Rate of Sampled Immunosuppressant in Typical Cities of China
Four Families in Cyclosporine Market
Immunosuppressant Markets in the U.S. and China
China Diabetes Market Scale and Its Growth, 2002-2006
Market Shares of Sampled Diabetes Medicines, 2005-2006
Market Shares of Pioglitazone Producers in 16 Chinese Sampled Cities
Top Ten Diabetes Medicine Producers in China, 2004-2006
Huadong Medicine's Revenue, Growth Rate and Profit Margin from Diabetes and Peptic Medicine, 2004-2008
Main Peptic Ulcer Drugs Applied in Clinic in China and their Market Shares
Proton Pump Inhibitor Main Products and Market Shares, 2004-2006
Pantoprazole Market Share and Growth, 2004-2006
Competition among Pantoprazole Producers
Competition among Omeprazole Producers
Huadong Medicine's Sales Revenue and Growth Rate, 2004-2008
Huadong Medicine's Specific Quality Standards for Bulk Raw Material Purchasing 
Growth of Huadong Medicine's Business 1998-2007
Huadong Medicine's Distribution Network
Huadong Medicine's Production, Sales, and Technical Team, 2006-2007
Products of General Agents above Designated Scale, 2005-2007
Ornidazole Applied for Gynecological Inflammation Disease, 2004-2006
Market Shares of Ornidazole
Huadong Medicine's Solvency
Huadong Medicine's Operation Efficiency 
Huadong Medicine's Profitability
Huadong Medicine's Growing Ability
Huadong Medicine's Financial Structure
Huadong Medicine's Cash Flows

Published Date

Number of Pages

Publisher

Price

May/2008

33

ResearchInChina

US$599(PDF)

US$599(Hard Copy)

US$1,200(Enterprise Wide)

Roport录入:wangyunling    责任编辑:wangyunling 
  • 上一barRoport:

  • 下一barRoport: 没有了
  • 【Comment】
    11
    关于我们 | 报告购买帮助 | 定制服务 | 关于佐思软件 | 会员服务申请 | 常见问题 | 版权申明 | 友情链接 | 联系我们
    2005-2008 OKOKOK.com.cn All rights reserved. 佐思信息 版权所有 京ICP证041200号
    北京:010-51266615  010-82863480/1/2/5 上海:021-64871266  021-64872612 传真:010-64872324
    Email: 地址:北京市海淀区五道口华清商务会馆906D(100083)


    PDF阅读软件